Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City S...
03 September 2013 - 3:00PM
Marketwired
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch"
or the "Company"), today announced it will be featured as a
presenting company at the 15th Annual Rodman & Renshaw Global
Investment Conference. The conference, sponsored by H.C. Wainwright
& Co., LLC, is being held September 8-10, 2013, at the
Millennium Broadway Hotel in New York City.
Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide
an overview of the Company's business during the live presentation
and will be available to participate in one-on-one meetings with
investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
(www.rodm.com) to register for the Rodman & Renshaw conference.
Once your registration is confirmed, you will be prompted to log
into the conference website to request a one-on-one meeting with
the Company.
Follow the official Rodman & Renshaw handle on Twitter
@Rodman_2013 and use #Rodman2013 for conference information and updates.
Event: 15th Annual Rodman & Renshaw Global Investment
Conference Date: Tuesday September 10, 2013 Time: 8:45am (Eastern
Time) Location: Room 7.02 (7th floor); Millennium Broadway Hotel in
New York City
The presentation will be webcast live. To access the webcast,
please visit: http://wsw.com/webcast/rrshq23/ARTH.
The webcast replay will remain available for 90 days following
the live presentation.
About Arch Therapeutics, Inc. (OTCQB:
ARTH) Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device
company developing a novel approach to stop bleeding (hemostasis)
and control leaking (sealant) during surgery and trauma care.
Arch's goal is to develop and commercialize products based on our
innovative technology platform that make surgery and interventional
care faster and safer for patients. Arch's flagship development
stage product candidate known as AC5™ is being designed to
elegantly achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at www.archtherapeutics.com.
About Rodman & Renshaw Conferences,
LLC The Rodman & Renshaw Annual Global Investment
Conference is an informational service and networking opportunity
for companies and investors. Rodman does not prepare, review or
edit the presentations and other information provided by each
company, and does not take any responsibility for the accuracy or
adequacy of any such information as the basis for any investment
decision. Rodman is not providing any person with any investment
advice through their participation in or attendance of the
Conference, nor is Rodman soliciting any offers to buy or sell any
security of any company.
Notice Regarding Forward-Looking
Statements This news release contains "forward-looking
statements" as that term is defined in Section 27(a) of the
Securities Act of 1933, as amended, and Section 21(e) of the
Securities Exchange Act of 1934, as amended. Statements in this
press release that are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references
to novel technologies and methods, our business and product
development plans and projections, or market information. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company, our ability to retain important members of our management
team and attract other qualified personnel, our ability to raise
the additional funding we will need to continue to pursue our
business and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board, Terrence W. Norchi, MD. Arch
Therapeutics, Inc.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: ARTH Investor Relations Toll Free:
+1-855-340-ARTH (2784) (US and Canada) Email:
investors@archtherapeutics.com Website:
www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024